| Lizenz: Creative Commons Namensnennung-KeineBearbeitung 4.0 International PDF - Veröffentlichte Version (3MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-415776
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.41577
Zusammenfassung
Binding of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to the plasma membrane TRAIL-R1/-R2 selectively kills tumor cells. This discovery led to evaluation of TRAIL-R1/-R2 as targets for anti-cancer therapy, yet the corresponding clinical trials were disappointing. Meanwhile, it emerged that many cancer cells are TRAIL-resistant and that TRAIL-R1/R2-triggering may lead to ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Downloadstatistik